Table 2. Univariate and analysis and MVA... | American Society of Hematology

Table 2.

Univariate and analysis and MVA for PFS using stratified Cox regression adjusted for treatment center

	RT PFS (38 events)			Combined modality therapy PFS (31 events)
Variable	Univariate	MVA1	MVA2*	Univariate	MVA
Age (continuous)
HR	1.01	—	—	1.02	1.02
95% CI	0.99-1.04			1.01-1.04	0.99-1.04
P	.24			.009	.08
Male sex
HR	1.17	—	—	2.07	—
95% CI	0.59-2.35			0.90-4.78
P	.65			.09
B symptoms
HR	—	—	—	2.39	1.91
95% CI				1.25-4.56	1.01-3.63
P				.008	.047
Bone marrow biopsy
HR	0.70	—	—	1.02	—
95% CI	0.41-1.20			0.50-2.11
P	.20			.95
Extranodal disease
HR	1.58	—	—	1.00	—
95% CI	0.53-4.67			0.22-4.61
P	.41			1.00
Stage II
HR	1.35	—	—	2.26	2.04
95% CI	0.68-2.69			1.01-5.07	0.85-4.90
P	.40			.048	.11
Noncontiguous stage II
HR	0.76	—	—	0.76	—
95% CI	0.18-3.13			0.23-2.55
P	.70			.66
Pretreatment size (continuous), cm
HR	1.06	—	—	1.03	—
95% CI	0.98-1.13			0.95-1.11
P	.47			.47
PET staged
HR	0.98	—	—	1.00	—
95% CI	0.40-2.44			0.47-2.12
P	.97			1.00
Number of involved sites >2
HR	2.51	2.66	2.66	1.19	—
95% CI	1.17-5.40	1.33-5.32	1.23-5.75	0.26-5.40
P	.02	.006	.01	.43
Infradiaphragmatic
HR	0.22	0.22	0.24	0.56	—
95% CI	0.06-0.79	0.07-0.70	0.04-1.46	0.20-1.60
P	.02	.01	.12	.28
Variant IAP†
HR	2.46	—	2.70	0.51	—
95% CI	1.06-5.66		1.14-6.40	0.05-5.22
P	.04		.02	.57

	RT PFS (38 events)			Combined modality therapy PFS (31 events)
Variable	Univariate	MVA1	MVA2*	Univariate	MVA
Age (continuous)
HR	1.01	—	—	1.02	1.02
95% CI	0.99-1.04			1.01-1.04	0.99-1.04
P	.24			.009	.08
Male sex
HR	1.17	—	—	2.07	—
95% CI	0.59-2.35			0.90-4.78
P	.65			.09
B symptoms
HR	—	—	—	2.39	1.91
95% CI				1.25-4.56	1.01-3.63
P				.008	.047
Bone marrow biopsy
HR	0.70	—	—	1.02	—
95% CI	0.41-1.20			0.50-2.11
P	.20			.95
Extranodal disease
HR	1.58	—	—	1.00	—
95% CI	0.53-4.67			0.22-4.61
P	.41			1.00
Stage II
HR	1.35	—	—	2.26	2.04
95% CI	0.68-2.69			1.01-5.07	0.85-4.90
P	.40			.048	.11
Noncontiguous stage II
HR	0.76	—	—	0.76	—
95% CI	0.18-3.13			0.23-2.55
P	.70			.66
Pretreatment size (continuous), cm
HR	1.06	—	—	1.03	—
95% CI	0.98-1.13			0.95-1.11
P	.47			.47
PET staged
HR	0.98	—	—	1.00	—
95% CI	0.40-2.44			0.47-2.12
P	.97			1.00
Number of involved sites >2
HR	2.51	2.66	2.66	1.19	—
95% CI	1.17-5.40	1.33-5.32	1.23-5.75	0.26-5.40
P	.02	.006	.01	.43
Infradiaphragmatic
HR	0.22	0.22	0.24	0.56	—
95% CI	0.06-0.79	0.07-0.70	0.04-1.46	0.20-1.60
P	.02	.01	.12	.28
Variant IAP†
HR	2.46	—	2.70	0.51	—
95% CI	1.06-5.66		1.14-6.40	0.05-5.22
P	.04		.02	.57

—, regression did not converge.

MVA2 performed using the subset with IAP available.

Subset with IAP available: RT cohort (n = 100; 22 events); CMT cohort (n = 76; 12 events).